Basics 4D Molecular Therapeutics, Inc. IPO Date: December 11, 2020 Sector: Healthcare Industry: Biotech Market Cap: $611.35M Activated in VL: True Average Daily Range Avg Daily Range: $0.62 | 3.59% Avg Daily Range (30 D): $0.43 | 3.90% Avg Daily Range (90 D): $0.36 | 4.33% Institutional Daily Volume Avg Daily Volume: .43M Avg Daily Volume (30 D): .82M Avg Daily Volume (90 D): 1.06M Trade Size Avg Trade Size (Sh.): 74 Avg Trade Size (Sh.) (30 D): 72 Avg Trade Size (Sh.) (90 D): 88 Institutional Trades Total Inst.Trades: 1,099 Avg Inst. Trade: $1.82M Avg Inst. Trade (30 D): $.87M Avg Inst. Trade (90 D): $1.07M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.8M Avg Closing Trade (30 D): $.71M Avg Closing Trade (90 D): $.79M Avg Closing Volume: 100.11K     News Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc. Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai Aug 11, 2025 @ 12:00 PM 4DMT Reports Second Quarter 2025 Financial Results... Source: 4D Molecular Therapeutics Financials   TTM Q3 2025 Q2 2025 Basic EPS $-3.75 $-1.01 $-.98 Diluted EPS $-3.75 $-1.01 $-.98 Revenue $ .12M $ .09M $ .02M Gross Profit $ $ $ Net Income / Loss $ -209.18M $ -56.88M $ -54.66M Operating Income / Loss $ -230.38M $ -61.19M $ -59.46M Cost of Revenue $ $ $ Net Cash Flow $ -138.98M $ -28.6M $ -72.18M PE Ratio